For drug repositioning purposes, the family of G-protein-coupled receptors (GPCRs), representing the largest family of targets for already approved drugs, may offer adequate candidates for novel HF indications, since these are importantly involved in the physiology and pathophysiology of cardiovascular diseases [8]. The gene discussed is EDNRA; the disease is hydrops fetalis.